REGN SEC Filing News — Regeneron Pharmaceuticals, Inc.

Latest SEC filings for Regeneron Pharmaceuticals, Inc. (REGN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2026-07-30.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul…
Sector: Healthcare Industry: Biotechnology Market Cap: $78.5B CIK: 872589
20
Total Filings
0
Bullish Signals
7
Bearish Signals
7
Insider Transactions
6
Material Events (8-K)
3
Periodic Reports
Insider activity for REGN has skewed bearish recently. Of the 20 filings tracked, 7 carry bearish signals (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
REGN Filing Activity Snapshot 2026-01-30 — 2026-07-30
Insider Transactions (Form 4)
0 buys vs 7 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Transaction
$3.19M
Pitofsky Jason · 2026-02-09
2,036 shares · Form 144
Form 144 Notices
4
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Recent SEC Filings
Form 10-Q Quarterly Report 2026-07-30

REGN filed Quarterly Report (10-Q)

REGENERON PHARMACEUTICALS, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-30

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 4 Insider Selling 2026-07-07

REGN insider RYAN ARTHUR F (Director) sold 200 shares (~$130.0K)

RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 200 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

Filing: Form 4 (Insider Transaction) Insider: RYAN ARTHUR F (Director) Shares: 200 Est. Value: $130.0K
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-06

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-02

REGN Form 144 filed for proposed insider sale by Arthur F. Ryan (400 shares) ~$499.8K

Arthur F. Ryan filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Arthur F. Ryan Shares: 400 Est. Value: $499.8K
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-17

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 4 Insider Selling 2026-05-04

REGN insider RYAN ARTHUR F (Director) sold 100 shares (~$70.5K)

RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 100 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

Filing: Form 4 (Insider Transaction) Insider: RYAN ARTHUR F (Director) Shares: 100 Est. Value: $70.5K
View on SEC EDGAR → Open Filing Document →
Form 10-Q Quarterly Report 2026-04-29

REGN filed Quarterly Report (10-Q)

REGENERON PHARMACEUTICALS, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-04-29

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-04-08

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 4 Insider Selling 2026-04-03

REGN insider RYAN ARTHUR F (Director) sold 100 shares (~$77.7K)

RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 100 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

Filing: Form 4 (Insider Transaction) Insider: RYAN ARTHUR F (Director) Shares: 100 Est. Value: $77.7K
View on SEC EDGAR → Open Filing Document →
Form 4 Insider Selling 2026-03-03

REGN insider RYAN ARTHUR F (Director) sold 100 shares (~$78.5K)

RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 100 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

Filing: Form 4 (Insider Transaction) Insider: RYAN ARTHUR F (Director) Shares: 100 Est. Value: $78.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Insider Selling 2026-02-23

REGN insider Zoghbi Huda Y (Director) sold 1,638 shares (~$1.28M)

Zoghbi Huda Y, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 1,638 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

Filing: Form 4 (Insider Transaction) Insider: Zoghbi Huda Y (Director) Shares: 1,638 Est. Value: $1.28M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-02-19

REGN Form 144 filed for proposed insider sale by Zoghbi Huda Y (1,638 shares) ~$2.59M

Zoghbi Huda Y filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Zoghbi Huda Y Shares: 1,638 Est. Value: $2.59M
View on SEC EDGAR → Open Filing Document →
Form 4 Insider Selling 2026-02-11

REGN insider Pitofsky Jason (SVP Controller) sold 2,036 shares (~$1.59M)

Pitofsky Jason, listed as SVP Controller at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 2,036 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

Filing: Form 4 (Insider Transaction) Insider: Pitofsky Jason (SVP Controller) Shares: 2,036 Est. Value: $1.59M
View on SEC EDGAR → Open Filing Document →
Form 4 Insider Selling 2026-02-11

REGN insider RYAN ARTHUR F (Director) sold 100 shares (~$77.9K)

RYAN ARTHUR F, listed as Director at REGENERON PHARMACEUTICALS, INC., reported an open-market sale of 100 REGN shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

Filing: Form 4 (Insider Transaction) Insider: RYAN ARTHUR F (Director) Shares: 100 Est. Value: $77.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-02-09

REGN Form 144 filed for proposed insider sale by Arthur F. Ryan (400 shares) ~$628.4K

Arthur F. Ryan filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Arthur F. Ryan Shares: 400 Est. Value: $628.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-02-09

REGN Form 144 filed for proposed insider sale by Pitofsky Jason (2,036 shares) ~$3.19M

Pitofsky Jason filed a Form 144 with the SEC indicating intent to sell REGN (REGENERON PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Pitofsky Jason Shares: 2,036 Est. Value: $3.19M
View on SEC EDGAR → Open Filing Document →
Form 10-K Annual Report 2026-02-04

REGN filed Annual Report (10-K)

REGENERON PHARMACEUTICALS, INC. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-01-30

REGN filed 8-K — material company event

REGENERON PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →

Understanding Regeneron Pharmaceuticals, Inc.'s SEC Filings

Form 4 — Insider Transactions

Executives, directors, and large shareholders must report any purchase or sale of REGN shares within two business days. Consistent buying by multiple insiders is often read as a confidence signal; large sales may reflect diversification or liquidity needs rather than negative conviction.

Form 144 — Proposed Insider Sales

Filed when a company affiliate intends to sell restricted or control shares. A Form 144 is a notice of intent, not confirmation — the actual sale is later confirmed via Form 4. It gives investors advance visibility into planned insider selling activity.

8-K — Material Events

The 8-K is an event-driven filing that Regeneron Pharmaceuticals, Inc. must submit within four business days of a significant development — including earnings results, mergers, executive changes, credit facility updates, or regulatory actions. Each 8-K item code maps to a specific event type.

10-Q & 10-K — Periodic Reports

The 10-Q (quarterly) and 10-K (annual) are comprehensive reports covering Regeneron Pharmaceuticals, Inc.'s financial results, risk factors, management discussion, and business operations. The 10-K includes audited financials and is the most complete public disclosure the company makes each year.

Frequently Asked Questions — REGN SEC Filings

What SEC filings does Regeneron Pharmaceuticals, Inc. submit to the SEC?

Regeneron Pharmaceuticals, Inc. (REGN) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about REGN?

A Form 4 for REGN discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the date, number of shares bought or sold, the price, and the insider's updated total ownership. Consistent insider buying across multiple executives is often interpreted as a bullish signal.

How do I interpret an 8-K filing from Regeneron Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for REGN?

The 10-K is Regeneron Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all REGN SEC filings directly on EDGAR?

You can view all historical Regeneron Pharmaceuticals, Inc. filings on the SEC EDGAR company page for REGN. Each filing card on this page links directly to the original SEC document.

How often does Regeneron Pharmaceuticals, Inc. file with the SEC?

Regeneron Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling REGN shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for REGN

REGN Full Stock Analysis REGN Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Demand Zone Analyzer Sector Scanner Browse All Stocks

Want deeper REGN analysis?

View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the REGN stock analysis page.

REGN Full Analysis
SEC filing data is sourced from SEC EDGAR. This page is updated automatically as new filings are detected. Content is for informational purposes only and does not constitute investment advice. Full Disclaimer.